Cargando…

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center

PURPOSE: Until now, most long-term results for brachytherapy only has been published for low-dose-rate (LDR) seeds. Due to radiobiology reasons, high-dose-rate (HDR) mono-brachytherapy is of growing interest. The aim of the study was to report long-term biochemical control rate and toxicities with H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansson, Bengt, Olsén, Johan Staby, Karlsson, Leif, Lundin, Erik, Lennernäs, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170525/ https://www.ncbi.nlm.nih.gov/pubmed/34122563 http://dx.doi.org/10.5114/jcb.2021.105846

Ejemplares similares

Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer
por: Olsén, Johan Staby, et al.
Publicado: (2022)

An audit of high dose-rate prostate brachytherapy treatment planning at six Swedish clinics
por: Dohlmar, Frida, et al.
Publicado: (2021)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
por: Barnes, Justin, et al.
Publicado: (2019)

The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer
por: Karlsson, Leif, et al.
Publicado: (2014)

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
por: Yoshioka, Yasuo, et al.
Publicado: (2013)

High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
por: Yoshioka, Yasuo, et al.
Publicado: (2014)

Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer
por: Contreras, Jessika A., et al.
Publicado: (2015)

Pulsed dose rate brachytherapy as the boost in combination with external beam irradiation in base of tongue cancer. Long-term results from a uniform clinical series
por: Johansson, Bengt, et al.
Publicado: (2011)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Long term results of PDR brachytherapy for lip cancer
por: Johansson, Bengt, et al.
Publicado: (2011)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
por: Cendales, Ricardo, et al.
Publicado: (2015)

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up
por: Behmueller, Manuel, et al.
Publicado: (2021)

Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience
por: Barnes, Justin M., et al.
Publicado: (2019)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2020)

A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
por: Potharaju, Mahadev, et al.
Publicado: (2015)

High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis
por: Anderson, Eric M., et al.
Publicado: (2021)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy
por: Burchardt, Wojciech M., et al.
Publicado: (2023)

High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience
por: Soatti, Carlo Pietro, et al.
Publicado: (2020)

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer
por: Ghadjar, Pirus, et al.
Publicado: (2014)

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer
por: Guirado, Damián, et al.
Publicado: (2020)

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
por: Tselis, Nikolaos, et al.
Publicado: (2013)

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
por: Anderson, Elliot, et al.
Publicado: (2021)

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
por: Boehle, Andreas, et al.
Publicado: (2022)

High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2018)

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
por: Nakamura, Satoshi, et al.
Publicado: (2016)

Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up
por: Vuolukka, Kristiina, et al.
Publicado: (2020)

High dose-rate brachytherapy in the treatment of prostate cancer
por: Mendez, Lucas C., et al.
Publicado: (2018)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

Ten‐step method of high‐dose LDR (125)I brachytherapy for intermediate‐risk prostate cancer
por: Okamoto, Keisei
Publicado: (2021)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Biological dose summation of intensity-modulated arc therapy and image-guided high-dose-rate interstitial brachytherapy in intermediate- and high-risk prostate cancer
por: Fröhlich, Georgina, et al.
Publicado: (2020)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
por: Khanolkar, Rutvij A., et al.
Publicado: (2021)

A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy
por: Slevin, Finbar, et al.
Publicado: (2019)

Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife
por: Fukuda, Shoichi, et al.
Publicado: (2014)

Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options
por: Skowronek, Janusz
Publicado: (2013)

3D image-based adapted high-dose-rate brachytherapy in cervical cancer with and without interstitial needles: measurement of applicator shift between imaging and dose delivery
por: Karlsson, Leif, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_trblhdkm99a0cs1ttphheb9r12